ETON
BUYNeutralComposite
73.20
Technical
92.90
Fundamental
60.10
Rank
—
Price
62.67
Hurst
0.51
As of
Aug 28, 2026
Daily
Eton Pharmaceuticals, Inc.
HealthcareDrug Manufacturers - Specialty & GenericEton Pharmaceuticals develops and sells medications for uncommon genetic and metabolic disorders. The company's marketed portfolio includes treatments for conditions such as growth hormone deficiency, adrenal insufficiency, Wilson disease, and various metabolic disorders affecting amino acid processing. Its pipeline includes several candidates in advanced stages targeting conditions like diabetes insipidus, neonatal diabetes, and adrenal crisis.
Market cap
$1.5B
P/E (trailing)
130.45
P/E (forward)
20.46
PEG ratio
—
Dividend yield
0.00%
Beta
0.90
52w range
14.27 – 66.37
Return on equity
+35.97%
Profit margin
+12.02%
Revenue growth
+98.60%
Earnings growth
—
Price history
1Y: 52.18 (+189.7%) · range 14.35–64.43
Cycle position
40/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 40 · WEAK SETUP · exit proximity 15
Conviction
33/ 100 · maturity 0%
Buildup.334
EMA entry setup.4240
Fundamentals.2560
Volume profile
POC
55.65
Price vs POC
-6.2%
Overhead supply
43%
Runway
+5.1%
Value area 37.78–65.58 · 43% of 120d volume overhead · moderate overhead
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.00% | +3.65% | mature |
| 40d | -16.36% | +3.65% | 39/40d |